

21st June 2024

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURGSociete Anonyme35A Boulevard Joseph II,L-1840 Luxembourg

Dear Sir/Madam,

Sub: USFDA inspection at Company's manufacturing facility in Goa, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our earlier intimations on the captioned subject dated 28th September 2019, 22nd January 2020, 26th February 2020, 26th August 2022 and 24th November 2022, we hereby notify that the USFDA has conducted an inspection at the Company's manufacturing facility in Goa, India from 10th – 21st June 2024.

On conclusion of the inspection, the Company received 6 (six) inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Please take the above information on record.

Yours faithfully, For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode

Cipla Ltd.